Physician profile
Douglas Ahn
NPI 1609934025
$28,175.78
in general payments reported to CMS, 2019-2025
33 companies · $4,868 in 2025
The $4,868 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,001 · 2020: $1,600 · 2021: $2,737 · 2022: $4,764 · 2023: $4,964 · 2024: $5,242 · 2025: $4,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,701.24 |
| Education | $373.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,162.06 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $3,252.70 | 2019-2025 | Tremfya, Remicade, Simponi Aria |
| Pfizer INC. | $2,519.35 | 2019-2025 | |
| Leo Pharma INC. | $1,508.78 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $1,302.28 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,277.14 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $1,255.86 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,087.71 | 2019-2025 | Dupixent |
| Incyte Corporation | $1,054.65 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $1,023.75 | 2019-2025 | |
| Amgen INC. | $1,020.89 | 2019-2025 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,013.41 | 2019-2025 | Siliq, Targretin, Cabtreo |
| Ucb, INC. | $755.26 | 2019-2025 | Cimzia, Bimzelx |
| Dermavant Sciences, INC. | $525.41 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $498.90 | 2022-2025 | Sotyktu |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $408.98 | 2020-2025 | Nemluvio, Aklief |
| Celgene Corporation | $272.00 | 2019 | |
| Vyne Pharmaceuticals INC. | $266.45 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $145.43 | 2019 | |
| Janssen Scientific Affairs, LLC | $132.59 | 2019-2020 | |
| Prugen, INC. Pharmaceuticals | $115.15 | 2019 | |
| Sandoz INC. | $114.16 | 2019-2024 | Hyrimoz |
| Glaxosmithkline, LLC. | $97.24 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $71.56 | 2023 | Idacio |
| Almirall LLC | $56.76 | 2019 | |
| Arcutis Biotherapeutics, INC. | $53.05 | 2023-2024 | Zoryve |
| Organon LLC | $41.84 | 2025 | Vtama |
| Genentech USA, INC. | $37.74 | 2019 | |
| Dusa Pharmaceuticals, INC. | $23.34 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.81 | 2019 | |
| Therakos LLC | $21.75 | 2025 | Uvadex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.12 | 2019 | |
| Dermira, INC. | $16.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Ahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.